financetom
Business
financetom
/
Business
/
Cornerstone Strategic Investment Fund Insider Sold Shares Worth $284,900, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cornerstone Strategic Investment Fund Insider Sold Shares Worth $284,900, According to a Recent SEC Filing
Sep 5, 2025 2:36 PM

05:05 PM EDT, 09/05/2025 (MT Newswires) -- Matthew Morris, Director, on September 03, 2025, sold 35,000 shares in Cornerstone Strategic Investment Fund ( CLM ) for $284,900.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/814083/000139834425017745/xslF345X05/fp0095344-1.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bombardier Launching US$250 Million Offering Of Additional 6.75% Senior Notes Due 2033 To Repay Existing Debt
Bombardier Launching US$250 Million Offering Of Additional 6.75% Senior Notes Due 2033 To Repay Existing Debt
Sep 4, 2025
08:05 AM EDT, 09/04/2025 (MT Newswires) -- Plane maker Bombardier Inc. (BBD-A.TO, BBD-B.TO) launched Thursday an offering of US$250 million aggregate principal amount of senior notes due 2033. A statement noted the additional notes will be a further issuance of, and form a single series with, the existing $500 million aggregate principal amount of its 6.750% Senior Notes due 2033...
JetBlue Raises Q3 Outlook on Strong Summer Demand, Cuts Capital Spending Guidance
JetBlue Raises Q3 Outlook on Strong Summer Demand, Cuts Capital Spending Guidance
Sep 4, 2025
08:09 AM EDT, 09/04/2025 (MT Newswires) -- JetBlue Airways ( JBLU ) said Thursday for its third quarter ending Sept. 30, it expects Operating Revenue per Available Seat Mile to contract between 4% to 1.5%, down from its earlier outlook of 6% to 2% reduction. The company said that demand for air travel remained strong throughout the summer peak and...
C4 Therapeutics Says Biogen's IND Application Accepted by FDA to Treat Autoimmune Diseases
C4 Therapeutics Says Biogen's IND Application Accepted by FDA to Treat Autoimmune Diseases
Sep 4, 2025
08:11 AM EDT, 09/04/2025 (MT Newswires) -- C4 Therapeutics ( CCCC ) said Thursday that its partner Biogen's (BIIB) investigational new drug application for BIIB142, a degrader of IRAK4, was accepted by the US Food and Drug Administration. Biogen plans to explore the therapeutic use of BIIB142 in patients with autoimmune diseases, the biopharmaceutical company said. Under the terms of...
Agios Pharmaceuticals Says FDA Extends PDUFA Goal Date for Thalassemia Treatment NDA to Dec. 7
Agios Pharmaceuticals Says FDA Extends PDUFA Goal Date for Thalassemia Treatment NDA to Dec. 7
Sep 4, 2025
08:06 AM EDT, 09/04/2025 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Thursday the US Food and Drug Administration has extended the target date to approve the company's supplemental new drug application of Pyrukynd for treating adults with thalassemia by three months to Dec. 7. The agency requested a proposed risk evaluation and mitigation strategy to address potential liver...
Copyright 2023-2026 - www.financetom.com All Rights Reserved